Depemokimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | Interleukin 5 |
| Clinical data | |
| Trade names | Exdensur |
| Other names | AQ-82742999; GSK 294; GSK3511294, depemokimab-ulaa |
| AHFS/Drugs.com | exdensur |
| License data |
|
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| ChEMBL | |
Depemokimab, sold under the brand name Exdensur, is a humanized monoclonal antibody used for the treatment of asthma. Depemokimab is an interleukin-5 (IL-5) antagonist monoclonal antibody (humanized immunoglobulin G1 [IgG1] kappa). Depemokimab was developed by GSK. It is structurally similar to mepolizumab but contains seven amino acid substitutions in the heavy chain sequence.
Depemokimab was approved for medical use in both the United Kingdom and United States in December 2025.